Remyelinating antibody: Phase I data

A double-blind, placebo-controlled, U.S. Phase I trial in 72 MS patients showed that single ascending doses of

Read the full 179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE